P
Pharmesis International Ltd
SGX:BFK
Pharmesis International Ltd
SGX:BFK
Price:
0.355
SGD
Market Closed
Market Cap:
S$11.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Pharmesis International Ltd
SGX:BFK
|
CN |
|
Pendragon PLC
LSE:PDG
|
UK |
|
T
|
TTET Union Corp
TWSE:1232
|
TW |
|
InVision AG
XETRA:IVX
|
DE |
|
D
|
Devsisters Corp
KOSDAQ:194480
|
KR |
|
H
|
HLS Therapeutics Inc
OTC:HLTRF
|
CA |
|
S
|
State Bank of India
BSE:500112
|
IN |
|
Yingkou Jinchen Machinery Co Ltd
SSE:603396
|
CN |
|
S
|
SKK Holdings Ltd
NASDAQ:SKK
|
SG |
|
F
|
Fasoo Co Ltd
KOSDAQ:150900
|
KR |
|
Weed Inc
OTC:BUDZ
|
US |
|
A
|
Arrowroot Acquisition Corp
NASDAQ:AILE
|
US |
|
N
|
Northern Textiles And Garments JSC
VN:TET
|
VN |
|
West Holdings Corp
TSE:1407
|
JP |
|
Boeing Co
NYSE:BA
|
US |
|
Y
|
Yantai Eddie Precision Machinery Co Ltd
SSE:603638
|
CN |
|
Adolfo Dominguez SA
MAD:ADZ
|
ES |
|
BBR Holdings (S) Ltd
SGX:KJ5
|
SG |
|
D
|
Doosan Robotics Inc
KRX:454910
|
KR |
Multiples-Based Value
The Multiples-Based Value of one BFK stock under the Base Case scenario is hidden SGD. Compared to the current market price of 0.355 SGD, Pharmesis International Ltd is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BFK Multiples-Based Value
LOCKED
Multiples Across Competitors
BFK Competitors Multiples
Pharmesis International Ltd Competitors
Pharmesis International Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
P
|
Pharmesis International Ltd
SGX:BFK
|
11.3m SGD | 1.4 | -14.1 | -51.8 | -21.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
